Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance. (3rd September 2020)

• Record Type: Journal Article
• Authors: Tamma, Pranita D; Beisken, Stephan; Bergman, Yehudit; Posch, Andreas E; Avdic, Edina; Sharara, Sima L; Cosgrove, Sara E; Simner, Patricia J
• Is Part Of: Clinical infectious diseases. Volume 73:Number 11(2021)
• Page Start: e4599
• Page End: e4606
• Publication Date: 2020-09-03
• Subjects: antimicrobial resistance -- ceftazidime-avibactam -- AmpC -- DNA polymerase -- PBP3; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciaa1306
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Background: Ceftolozane-tazobactam (TOL-TAZ) affords broad coverage against Pseudomonas aeruginosa . Regrettably, TOL-TAZ resistance has been reported. We sought to identify modifiable risk factors that may reduce the emergence of TOL-TAZ resistance. Methods: Twenty-eight consecutive patients infected with carbapenem-resistant P. aeruginosa isolates susceptible to TOL-TAZ, treated with ≥72 hours of TOL-TAZ, and with P. aeruginosa isolates available both before and after TOL-TAZ exposure between January 2018 and December 2019 in Baltimore, Maryland, were included. Cases were defined as patients with at least a 4-fold increase in P. aeruginosa TOL-TAZ MICs after exposure to TOL-TAZ. Independent risk factors for the emergence of TOL-TAZ resistance comparing cases and controls were investigated using logistic regression. Whole genome sequencing of paired isolates was used to identify mechanisms of resistance that emerged during TOL-TAZ therapy. Results: Fourteen patients (50%) had P. aeruginosa isolates which developed at least a 4-fold increase in TOL-TAZ MICs(ie, cases). Cases were more likely to have inadequate source control (29% vs 0%, P = .04) and were less likely to receive TOL-TAZ as an extended 3-hour infusion (0% vs 29%; P = .04). Eighty-six percent of index isolates susceptible to ceftazidime-avibactam (CAZ-AVI) had subsequent P. aeruginosa isolates with high-level resistance to CAZ-AVI, after TOL-TAZ exposure and without any CAZ-AVI exposure. Common mutations identified in TOL-TAZ resistant isolates involved AmpC, a known binding site for both ceftolozane and ceftazidime, and DNA polymerase. Conclusions: Due to our small sample size, our results remain exploratory but forewarn of the potential emergence of TOL-TAZ resistance during therapy and suggest extending TOL-TAZ infusions may be protective. Larger studies are needed to investigate this association. Abstract : In 28 patients with Pseudomonas aeruginosa infections receiving ceftolozane-tazobactam (TOL-TAZ), 50% of isolates developed high-level TOL-TAZ resistance. TOL-TAZ infusion over 3 hours was protective against the emergence of resistance. Mutations in AmpC-AmpR and DNA polymerase were common in resistant isolates.